Stimcell Energetics INC 10-Q quarterly reports

Stimcell Energetics Inc. reported a wider net loss for the nine months ended February 28, 2026, driven by increased research and development costs for its eBalance device redesign, alongside significant related party transactions.

Stimcell Energetics Inc. reported a significant increase in net loss and a worsening working capital deficit for the six months ended November 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Stimcell Energetics Inc. reported a significantly increased net loss and a worsening working capital deficit for Q1 2026, raising substantial doubt about its ability to continue as a going concern.

Stimcell Energetics Inc. reports increased operating expenses and a net loss for Q3 2025, alongside ongoing concerns about its ability to continue as a going concern.

Stimcell Energetics Inc. reports a significant increase in operating expenses and net loss for the second quarter of fiscal year 2025, alongside a reverse stock split and name change.

Cell MedX Corp.'s Q1 2025 report reveals increased operating expenses and a continued net loss, highlighting the company's ongoing financial challenges.

Cell MedX Corp. released its Q3 2024 financial results, highlighting a significant debt conversion, a private placement, and changes in management.

Cell MedX Corp.'s Q2 2024 report reveals no revenue, a significant net loss, and a substantial working capital deficit, alongside a major debt-for-equity swap and management changes.